✅ EPS: $1.80 vs. $1.72 est. (+4.6% Y/Y)
✅ Revenue: $6.23B vs. $6.00B est. (+3.8% Y/Y)
• Core revenue growth driven by Life Sciences and Diagnostics
• Operating margin expanded modestly on cost discipline
• Reaffirmed FY25 guidance with steady cash flow performance
📊 Takeaway: Danaher delivered another solid quarter, beating expectations on both top and bottom lines. Strong execution in core segments and reaffirmed outlook underscore resilience amid a cautious macro backdrop.